Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions
Abstract One of the key pharmacokinetic properties of most small molecule drugs is their ability to bind to serum proteins. Unbound or free drug is responsible for pharmacological activity while the balance between free and bound drug can impact drug distribution, elimination, and other safety param...
Saved in:
Main Authors: | Jocelyn Courville (Author), Kathryn Roupe (Author), Gerhard Arold (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Re-discovering sandalwood: Beyond beauty and fragrance
by: Bhattacharjee Rajsmita, et al.
Published: (2019) -
A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib
by: Ling Gao, et al.
Published: (2023) -
Open-Label Study of the Safety and Pharmacokinetics of Solifenacin in Subjects With Hepatic Impairment
by: Mirjam Kuipers, et al.
Published: (2006) -
Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment
by: Rajinder Bhardwaj, et al.
Published: (2024) -
Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study
by: Smith WB, et al.
Published: (2012)